John Carroll

The XBI has plunged 27% since Donald Trump won the election, leaving the public markets an ugly mess for a biotech industry yearning for better times. Talk to CEOs these ...

Step back from the multitude of details that go into every big pharma pipeline, and you'll see the influence that blockbusters have on the entire field. These days, making your ...

RA Capital leads as most active venture player in private biotech rounds through 2024, with ARCH participating in fewer but larger rounds, per DealForma analysis.

Last week at JP Morgan, BioMarin CEO JJ Bienaimé laid out his thoughts on pricing the leading gene therapy for hemophilia A at $2 million to $3 million a shot. Payers would support that, he said, putting the biotech on track to launching a treatment that could top the price

It’s time for one last look at the biotech numbers for 2024. And you might be surprised by some bullish charts below — especially if you zero in on deal numbers ...

The Endpoints 100 is our semi-regular survey of biotech and pharma executives.

A survey of 77 biotech executives reveals concerns about FDA changes following Donald Trump's reelection. Martin Makary's nomination as FDA chief has eased some worries, while Robert F. Kennedy Jr.'s potential HHS leadership raises concerns. Most executives expect major policy changes, particularly regarding vaccines, though Makary's appointment from Johns Hopkins has provided some optimism for stability in drug development.

Some, though certainly not all, chief indicators of biotech business activity are pointed shakily north as we head into a critical Q4. But biotech shows signs of taking another step ...

It all started to look seriously bad when my legs began to swell up, which I initially — stupidly — shrugged off. By the time it became apparent that my kidneys had ...

This morning Faheem Hasnain is unveiling a $120 million private placement for his biotech, Gossamer Bio. Which says a lot about where and how the smart money is being bet ...

We are unleashing our nation’s scientific brilliance and will likely have a therapeutic and/or vaccine solution long before the end of the year.— Donald Trump, July 4Next week administration officials plan to promote a new study they say shows promising results on therapeutics, the officials said. They wouldn't describe the study in any further detail because, they said, its disclosure would be “market-moving.

James Sabry, the longtime doyen of biotech dealmakers from his global perch at Roche/Genentech, is jumping to the US biotech scene. The Basel-based pharma giant

DealForma’s Chris Dokomajilar has been running the numbers again and backs up some of the things we were already pretty sure about — while raising new questions about just how deep ...

Eli Lilly’s research division whipped up considerable fervor for its Phase II top-line readout on its next-gen Alzheimer’s drug donanemab. But after spelling out the data this weekend, you can ...

At a time when biotech is still counting its losses as a thaw gradually sets in after the long market winter, pharma has been on a tear. M&A took off ...

2023 marks one of those years in life sciences when venture capital spent a lot of time looking for ways to preserve cash runways and finding bridges to human data ...

The big pandemic boom that fueled some crazy numbers in biotech is long gone, as anyone in the industry who doesn’t reside in a sensory deprivation chamber knows. But biotech ...

When Chen Yu and his team at TCGX set out in early 2021 with some $800 million to invest in biotech, he had set out to fund ...

A lot of biotechs turned to survival mode back in the summer of 2022, and it’s clear from our recent surveys and panel discussions ...

There may be a sol­id chunk of ex­ec­u­tives in the End­points 100 who feel that bet­ter times are ahead for the biotech in­dus­try in 2024, but they’re still out­num­bered by doubters and the un­de­cid­ed. This H2 snap­shot of the opin­ions of 100+ biotech ex­ecs — the large ma­jor­i­ty of CEOs — found many are still re­cruit­ing new work­ers, but on­ly when ab­solute­ly nec­es­sary. The over­all tone re­mains dis­tinct­ly cau­tious in the wake of the post-pan­dem­ic plunge. Most CEOs — 70 re­s…